Modified gamma delta T cells and uses thereof
AssigneeTC Biopharm LTD
InventorsMichael David Leek, Adele Hannigan, Agapitos Patakas, Daria Paruzina
Life of this patent
Estimating the term…
Abstract
The present invention provides composition and methods for the treatment of cancer or infectious diseases in a human. The invention includes the generation and administration of gamma delta T cells that express chimeric antigen receptors (CARs) comprising an antigen binding domain, a hinge domain, a transmembrane domain, a costimulatory signalling domain with the inclusion or not of a CD3 zeta signalling domain. Expression of CAR sequence omitting the CD3 zeta signalling domain in gamma delta T cells, provides for a CAR-T therapy in vivo, which will effect cytolysis only on target cells providing ligands for activation of the gamma delta T cell receptor (TCR).
Claims8
A modified γδ T cell, comprising:
- (i) a γδ T cell receptor, wherein the γδ T cell receptor provides a T cell receptor (TCR) signal upon binding;
- and
- (ii) at least one co-stimulatory chimeric antigen receptor (CAR) wherein the co-stimulatory chimeric antigen receptor is a synthetic receptor to recognise and target a cell surface target, connected to a transmembrane domain which traverses the cell membrane and connects to an intracellular co-stimulatory signaling region capable of providing a co-stimulatory signal, wherein the at least one co-stimulatory CAR provides the co-stimulatory signal upon binding the cell surface target, and wherein the at least one co-stimulatory CAR does not provide a TCR cell receptor signal.
Dependencies are inferred from the claim text.